Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 87 от 154

Предстои набиране Фаза 4

Statins Against Bushfire Smoke

Healthy Adults

The goal of this clinical trial is to test whether statins can protect the heart and brain from the biological stress and inflammatory responses caused by breathing bushfire smoke in healthy adult volunteers aged 18-64 years. The main questions it aims to answer are: 1. Does short-term statin use (2 days) reduce bushfire smoke-induced changes in heart rate variability, blood pressure, arterial stiffness, inflammation and oxidative stress markers, and cognitive function? 2. Does long-term statin use (≥12 months) reduce bushfire smoke-induced changes in heart rate variability, blood pressure, arterial stiffness, inflammation and oxidative stress markers, and cognitive function? The study includes two streams: Stream 1:short-term statin use (2 days) where participants receive either statin tablets (80mg atorvastatin) or placebo; Stream 2: long-term statin use (≥12 months) where participants include those already taking statins (≥12 months) with statin-naïve individuals. Participants will: * Attend two 3½-hour visits to a Climate Hut, which are approximately 4 weeks apart, where they will spend 2 hours exposed to either filtered air or simulated dilute bushfire smoke (average particulate matter (PM2.5) concentration of 300μg/m\^3) in randomised order; * Have continuous heart monitoring with ECG leads and blood pressure checks every 15 minutes during each visit * Provide urine, saliva, and nose swab samples before and after each exposure, plus follow-up samples the next morning * Complete cognitive tests (reaction time, memory tasks) and postural balance measurements during exposure * Complete questionnaires about anxiety levels, symptoms, diet, and health status * Have blood samples collected and pulse wave velocity measurements (assessing arterial stiffness) immediately after each exposure session. Potential risks include time commitment, muscle pain from statins, eye irritation or throat discomfort from smoke exposure, and minor discomfort from blood collection.

Начало: 01.05.2026 Край: 31.12.2028 Възраст: 18–68 г. Лечение

Australia Menzies Institute for Medical Research NCT07462715

Предстои набиране Фаза 2

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Methamphetamine Use Disorder

Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.

Начало: 01.05.2026 Край: 01.03.2027 Възраст: от 18 г. Лечение

Australia Kirby Institute NCT07509112

Предстои набиране

Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation

Atrial Fibrillation

Pulsed Field Ablation (PFA) represents a recent advance in the treatment of atrial fibrillation (AF), with a safety profile potentially superior to traditional thermal techniques, such as radiofrequency or cryoablation. Its mechanism of action allows tissue selectivity which in theory limits damage to extracardiac structures. However, several cases of right diaphragmatic paralysis have been reported in the literature after PFA, particularly during applications on the right pulmonary veins, near the right phrenic nerve. The available data are from studies without specific diaphragmatic monitoring. The diagnosis of diaphragmatic paralysis is most often based on chest X-ray, a static examination of limited sensitivity, especially for the detection of incomplete paralysis. To date, no prospective multicentre study has evaluated the incidence of diaphragmatic paralysis after PFA with systematic dynamic imaging, such as fluoroscopy, considered the gold standard for the diagnosis of unilateral paralysis.

Начало: 01.05.2026 Край: 31.05.2027 Възраст: от 18 г. Диагностика

Canada, France, New Zealand French Cardiology Society NCT07462910

Предстои набиране Фаза 1

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Healthy Volunteers

A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses under fasted and fed conditions of ZE74-0282 administered orally in healthy volunteers.

Начало: 30.04.2026 Край: 01.01.2027 Възраст: 18–55 г. Лечение

Australia Eilean Therapeutics AU Pty Ltd NCT07527221

Предстои набиране Фаза 3

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

Obesity

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Начало: 21.04.2026 Край: 04.07.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +8 Novo Nordisk A/S NCT07503210

Предстои набиране Фаза 1

A Study of SA030 Injection in Overweight or Obese Participants

Obese Overweight

This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight or obese. Over the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.

Начало: 16.04.2026 Край: 03.03.2027 Възраст: 18–55 г. Лечение

Australia Suzhou Siran Biotechnology Co.,Ltd. NCT07479862

Предстои набиране Фаза 2

Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis

Clonal Cytopenia of Uncertain Significance CCUS Clonal Cytopenia of Undetermined Significance Clonal Hematopoiesis

Clonal hematopoiesis (CH) is characterized by the overproduction of blood cells derived from a single hematopoietic stem and progenitor cell (HSPC) harboring certain somatic mutations. It is linked to serious outcomes, including cardiovascular disease, myeloid neoplasm (MN), and increased mortality. Clonal Cytopenia of Uncertain Significance (CCUS) is a CH subtype characterized by associated persistent cytopenia. It affects approximately 10 % of people over 70 and is the most advanced precursor state with the highest risk of progressing to MN. There is an unmet need to determine whether modifying CH can prevent adverse outcomes. Current blood cancer therapies are too toxic for precursor conditions like CH. MOSAIC is a randomized double-blind placebo-controlled trial that will test a novel low-dose oral epigenetic therapy-decitabine with tetrahydrouridine (Dec+THU) in CCUS. It has shown targeted, non-cytotoxic reversal of common CH mutations in preclinical and early-phase studies. The goal is to develop a safe and effective therapy in CCUS that restores normal blood cell production and prevents progression.

Начало: 13.04.2026 Край: 01.10.2030 Възраст: 60–85 г. Лечение

Australia Clinical Hub for Interventional Research (CHOIR) NCT07435636

Предстои набиране Фаза 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity Overweight Osteoarthritis, Knee

This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Начало: 13.04.2026 Край: 17.07.2028 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +8 Novo Nordisk A/S NCT07509307

Предстои набиране Фаза 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity Knee Osteoarthritis (OA)

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Начало: 13.04.2026 Край: 17.07.2028 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +7 Novo Nordisk A/S NCT07481630

Предстои набиране Фаза 1

A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants

Healthy Volunteers

The main aim of the study is to evaluate the pharmacokinetic (PK) biosimilarity of B-3E07 and European Union (EU) - sourced Forsteo® in healthy adult female participants.

Начало: 10.04.2026 Край: 11.06.2026 Възраст: 18–45 г. Друго

Australia Syneos Health NCT07497503

Предстои набиране

Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (COOLHEAD-2b)

Stroke Acute Ischemic Stroke Brain Ischemia Ischaemic Stroke +5

COOLHEAD-2b is a multicentre, phase 2, prospective, randomised, controlled, open-label, blinded-endpoint trial evaluating the safety and efficacy of non-invasive convective head cooling as an adjunct to endovascular thrombectomy (EVT) in patients with acute anterior circulation ischaemic stroke. Head cooling is initiated as early as possible, including during inter-hospital transfer, and continued until one hour after reperfusion. The primary efficacy endpoint is final infarct volume at 24 hours.

Начало: 10.04.2026 Край: 30.06.2029 Възраст: от 18 г. Поддържаща грижа

New Zealand Auckland City Hospital NCT07526649

Предстои набиране Фаза 1/2

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

Metastatic Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels and dosing schedules of AZD8359 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD8359 doses in a larger group of participants (dose expansion).

Начало: 09.04.2026 Край: 11.10.2027 Възраст: 18–100 г. Лечение

Australia, South Korea, United States AstraZeneca NCT07529717

Предстои набиране Фаза 3

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).

Начало: 08.04.2026 Край: 29.08.2033 Възраст: 18–18 г. Лечение

Australia, Canada, Turkey (Türkiye) +1 AstraZeneca NCT07509151

Предстои набиране

Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

This study aims to collect information about the effects of chemotherapy combined with immunotherapy (immune checkpoint inhibitors) for early-stage triple-negative breast cancer (TNBC) on ovarian function and fertility. You may be eligible for this study if you have been diagnosed with early-stage TNBC and are planning to receive neoadjuvant chemotherapy combined with immunotherapy before surgery. Additional eligibility criteria apply. Participants who choose to enroll will be asked to complete questionnaires and provide blood samples before and after treatment to measure hormone levels related to ovarian function. Information about menstrual patterns, fertility preservation discussions, and reproductive health will also be collected. Some participants may undergo ultrasound assessments to evaluate ovarian reserve and endometrial thickness. Follow-up will continue for up to 24 months after treatment to assess long-term ovarian function. No additional or experimental cancer treatments will be provided as part of this study. This is an observational study only, and participants will receive standard cancer treatment as recommended by their treating team. It is hoped this research will provide important information about the potential effects of chemotherapy and immunotherapy on ovarian health and fertility in women receiving treatment for early-stage TNBC.

Начало: 08.04.2026 Край: 31.12.2031 Възраст: 18–42 г.

Australia Peter MacCallum Cancer Centre, Australia NCT07527819

Предстои набиране

Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion

Aortic Stenosis TAVI(Transcatheter Aortic Valve Implantation)

The goal of this clinical trial is to discover if routine 'double tap' balloon post-dilation improves valve expansion and clinical outcomes in adults undergoing Transcatheter Aortic Valve Implantation (TAVI) with the SAPIEN balloon-expandable TAVI prosthesis. The primary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve expansion. The secondary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve haemodynamic performance. Participants will be randomised to balloon-expandable TAVI either with or without routine 'double tap' balloon post-dilation.

Начало: 01.04.2026 Край: 01.04.2029 Възраст: от 18 г. Лечение

Australia The Alfred NCT07430267

Предстои набиране Фаза 2

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

Atherosclerosis Cardiovascular Disease ASCVD ASCVD Management

This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.

Начало: 01.04.2026 Край: 01.04.2028 Възраст: 18–75 г. Лечение

Australia, China, United States Atom Therapeutics Co., Ltd NCT07303777

Предстои набиране Фаза 1

Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women

Respiratory Syncytial Virus (RSV)

A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age

Начало: 01.04.2026 Край: 15.01.2027 Възраст: 18–49 г. Лечение

Australia MAXVAX Biotechnology Limited Liability Company NCT07492706

Предстои набиране

Exploration of Current and New Technologies for Accuracy of Diagnosing OSA

Obstructive Sleep Apnea

Resmed is the manufacturer of medical devices which screen, diagnose, treat and monitor people with sleeping and respiratory disorders, such as obstructive sleep apnea (OSA). From time to time, for regulatory, quality, and marketing purposes, there may be a need to test the various products performance against PSG (gold standard technology), and other products. The purpose of this study is: 1. Products performance against PSG 2. comparison against other products, and 3. Assessments of potential new technologies

Начало: 01.04.2026 Край: 01.10.2026 Възраст: от 18 г.

Australia ResMed NCT07485582

Предстои набиране

TAG TEAM - Trans Adolescent Group Therapy

Minority Stress Acceptability Psychological Distress Anxiety +6

This project will study the effect of the TAG TEAM group CBT program on the mental health of trans and gender diverse adolescents. TAG TEAM was co-designed by researchers and clinicians with a group of trans and gender diverse young people to help trans and gender diverse adolescents understand and cope with minority stress. Minority stress includes experiences like discrimination and rejection. TAG TEAM focuses on learning and practicing skills to support mental health and wellbeing. It also includes group discussions and activities with other trans and gender diverse young people. TAG TEAM groups are run by a psychologist and a trans peer facilitator. A trans peer facilitator is a trans and gender diverse person who is there to share their experience of being trans and to support participants in the group sessions.

Начало: 01.04.2026 Край: 01.03.2027 Възраст: 12–17 г. Лечение

Australia Murdoch Childrens Research Institute NCT07151079

Предстои набиране Фаза 1

A Phase 1 Study of Cizutamig in IgE Mediated Diseases

IgE-Mediated Hypersensitivity IgE Mediated Food Allergy IgE-Mediated Cow Milk Allergy

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.

Начало: 01.04.2026 Край: 01.12.2026 Възраст: 18–65 г. Лечение

Australia Candid Therapeutics NCT07408869

1 … 85 86 87 88 89 … 154